FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant

Page 1 of 1

ATTY. DOCKET NO.	SERIAL NO.
0269.01/C	10/652,814
APPLICANT	
Unger	
FILING DATE	GROUP
August 29, 2003	1633

	U.S. PATENT DOCUMENTS								
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	C L S	SUB- CLS	FILE DATE		
	AA	6,489,458	12/3/2002	HACKETT, ET AL.					
	AB	US 2003/087323	10/23/2009	UNGER					
	AC	US 2004/0038303	2/26/2004	UNGER					
	AD	US 2004/0038406	2/26/2004	UNGER					
	AE	US 2008/0113932 A1	05/15/2008	SLATON, ET AL.					
	AF	US 2008/0220072 A1	09/11/2008	UNGER, ET AL.					
	AG	US 2009/0238883	9/24/2009	KREN, ET AL.					

	FOREIGN PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS
	AH	WO 08/095192	8/7/2008	PCT			
	AI	WO 08/157514	12/24/2008	PCT			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AJ	Cook (1998) Antisense Medicinal Chemistry, Springer, New York, pp.51-101.
AK	Dresser, MJ (2001) "The MDR1 C3425T polymorphism: effects on P-glycoprotein expression/function and clinical significance," AAPS PharmSci, 3(23):3, Clinical Pharmacology
AL	Handbook of Pharmaceutical Excipients, (Arthur H. Kibbe, Ph.D., ed. American Pharmaceutical Association 2000) (1986)
AM	Halin et al., (2002) "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature," Nature Biotech 20:264-269.
AN	Heidel, Jeremy et al., (2005) "Molecular Conjugates," Adv. Biochem. Engin./Biotechnol: 99, 7-39.
AO	Kong, Garheng et al., (2000) "Hyperthermia Enables Tumor-specific Nanoparticle Delivery: Effect of Particle Size," Cancer Research, 60:4440-4445.
AP	Nagano et al., "Extracellular matrix modulates the proliferation of rat astrocytes in serum-free culture," Glia, 8:71-76
AQ	Schneider, Holm et al., (1999) "Targeted gene delivery into α ₉ β ₁ -integrin-displaying cells by a synthetic peptide," FEBS Letters, 458:329-332.
AR	Smith, James G. and Ho, Isaac, (1972) "The Reductive Dimerization of Schiff Bases by Alkali Metals. Isomerization of the Dimeric Dianions," Journal of Organic Chemistry, 37(4):653-656.
AS	S.T. CROOKE, Chapter 1: Basic Principles on Antisense Therapeutics pp. 1-50.
AT	Summerton and Weller (1997) Antisense Nuc. Acid Drug Devel. 7:187-195.
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

List of Information Cited by Applicant

Page 2 of 2

ATTY. DOCKET NO.	SERIAL NO.	
0269.01/C	10/652,814	
APPLICANT		
Unger		
FILING DATE	GROUP	
August 29, 2003	1633	

	U.S. PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						
	AAA						
	ABB						
	ACC						

August 29, 2003

	FOREIGN PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS
	BA						
	BB						
	BC						

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	BD	Wang (2006) "CK2 Signaling in androgen-dependent and independent prostate cancer" J. Cell Biochem. 99(2):382-391.
	BE	Wong (1991) "Chemistry of Protein Conjugation and Cross-Linking" CRC Press
	BF	Yamamoto et al., (1999) "Induction of Tenascin-C in Cardiac Myocytes by Mechanical Deformation," J. Biol. Chem. 274(31):21840-21846.
	BG	Yuan et al., (1994) "Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (Stealth) Liposomes in a Human Tumor Xenografi" Cancer Research 54:3352-3356.
	ВН	Zhang et al., (1997) "Comparision of Integrins in Human Skin, Pig Skin, and Perfused Skin: An In Vitro Skin Toxicology Model" Journal of Applied Toxicology 17(4):247-253
EXAMINER		DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

S:\ClientFolders\0269 (Gene Segues, Inc)\01\C\IDS 12.doc